3-Amino-1H-pyrazolo[3,4-b]quinoxaline

Cyclin-dependent kinases (Cdks) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. Cdk1/5 Inhibitor is a pyrazolo [3,4-b] quioxaline that inhibits Cdk1/cyclin B and Cdk5/p25 (IC₅₀s = 600 and 400 nM, respectively). It less potently inhibits GSK3β (IC₅₀ = 1 μM) and does not block Cdc25 activity. This compound is used to help define the roles of Cdk1 and Cdk5 in various signaling pathways.

Cyclin-dependent kinases (CDKs) are protein kinases and involved with the regulation of the cell cycle. NSC 693868 is an inhibitor of Cdk1/cyclin B and Cdk5/p25.Small molecules that target these protein kinases are valuable tools for investigating cellular signaling pathways and are potential therapeutic agents.

ChEBI: 2H-pyrazolo[4,3-b]quinoxalin-3-amine is a quinoxaline derivative.

Inhibitor of cyclin-dependent kinases (cdks) and glycogen synthase kinase-3 (GSK-3). IC 50 values are 0.6, 0.4 and 1 μ M for cdk1/cyclin B, cdk5/p25 and GSK-3 respectively.

Cdk1/cyclin B: 600 nM (IC₅₀); Cdk5/p25: 400 nM (IC₅₀); GSK-3β: 1 μM (IC₅₀)

[1] MIGUEL A. ORTEGA . Pyrazolo[3,4-b]quinoxalines. A new class of cyclin-Dependent kinases inhibitors[J]. Bioorganic & Medicinal Chemistry, 2002, 10 7: Pages 2177-2184. DOI: 10.1016/s0968-0896(02)00069-x
[2] SHAOYONG CHEN. Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103 43: 15969-15974. DOI: 10.1073/pnas.0604193103
[3] TRI K NGUYEN  Steven G. Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism.[J]. Molecular Cancer Therapeutics, 2014: 662-674. DOI: 10.1158/1535-7163.mct-13-0714
[4] SUPACHAI TOPANURAK. High NaCl- and urea-induced posttranslational modifications that increase glycerophosphocholine by inhibiting GDPD5 phosphodiesterase.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2013: 7482-7487. DOI: 10.1073/pnas.1305220110